New diagnostic and treatment targets in cartilage tumours
Finding New Diagnostic and Therapeutic Targets in Cartilaginous Tumours
St. Anne's University Hospital Brno, Czech Republic · NCT07315542
This project will test whether IDH1/2 gene changes and specific microRNA signals in tumour tissue and blood can help diagnose and guide treatment for people with cartilage tumours including chondrosarcoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | St. Anne's University Hospital Brno, Czech Republic (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Brno, South Moravian) |
| Trial ID | NCT07315542 on ClinicalTrials.gov |
What this trial studies
This observational project collects tumour tissue and blood (liquid biopsy) from patients with cartilaginous tumours to search for molecular biomarkers. Investigators will analyze tumour DNA for IDH1/2 mutations and profile non-coding microRNAs, with molecular validation in the laboratory. Results will be compared with pathology, imaging, and clinical outcomes to help distinguish benign cartilage lesions from low-grade and higher-grade chondrosarcoma and from other bone sarcomas. The work is conducted at St. Anne's University Hospital Brno in collaboration with Masaryk University and includes biobanking and molecular validation steps.
Who should consider this trial
Good fit: People with histologically confirmed cartilaginous tumours (enchondroma, atypical cartilaginous tumour/grade 1, conventional grade 2–3 chondrosarcoma, dedifferentiated or other variants) who are treated and/or followed at St. Anne's University Hospital Brno are ideal candidates.
Not a fit: Patients who do not have sufficient or usable tissue samples, or who are not treated/followed at the Brno center, are not eligible and would not benefit from participation.
Why it matters
Potential benefit: If successful, these markers could improve diagnostic accuracy, better predict tumour behavior, and point to targeted treatment options for patients with chondrosarcoma.
How similar studies have performed: IDH1/2 mutations are already known to be common and diagnostically useful in central chondrosarcoma and have been explored therapeutically in other cancers, while microRNA-based markers remain more exploratory.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Histologically confirmed cartilaginous (chondroid) tumour * Diagnosis includes one of the following entities (as available and eligible): * Enchondroma * Atypical cartilaginous tumour / Grade 1 chondrosarcoma (ACT/G1) * Conventional chondrosarcoma (Grade 2-3) * Dedifferentiated chondrosarcoma * Other rare chondrosarcoma variants (e.g., mesenchymal, clear-cell), if present in the cohort * Patients treated and/or followed at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno Exclusion Criteria * Insufficient, degraded, or otherwise unusable tissue samples
Where this trial is running
Brno, South Moravian
- First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia — Brno, South Moravian, Czechia (RECRUITING)
Study contacts
- Principal investigator: Tomáš Tomáš, Assoc.Prof., M.D., Ph.D. — Faculty of Medicine, Masaryk University, Brno, 60200, Czechia
- Study coordinator: Vasileios Apostolopoulos, M.D., Ph.D.
- Email: vasileios.apostolopoulos@fnusa.cz
- Phone: +420722101065
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chondrosarcomas, Cartilage Tumours, Chondrosarcoma, Liquid biopsy, Targeted therapy, Prognostic markers, Molecular biomarkers, MicroRNA